Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …

Investigators are using checkpoint inhibitors (CPIs) to treat aggressive hematologic
malignancies in patients undergoing allogeneic hematopoietic stem cell transplantation (allo …

Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication
(ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after …

Chimeric antigen receptor (CAR) T‐cell therapy has brought a paradigm shift in the
management of haematological malignancies and has opened novel avenues of …

Haematopoietic stem cell transplantation (HSCT) is central to the management of many
haematological disorders. A frequent complication of HSCT is acute graft-versus-host …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective
treatment for selected patients with acute myeloid leukemia (AML) and relies on a “graft …

Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT)
in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable …

Technological advances in the laboratory have led to substantial improvements in clinical
decision making through the introduction of pretreatment prognostic risk stratification factors …

Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation
(allo-HCT) has a dismal prognosis. We found that T cells of patients relapsing with AML after …

We conducted a phase 2 study to determine the efficacy of HLA-haploidentical related donor
natural killer (NK) cells after cyclophosphamide-based lymphodepletion in patients with …